Diaceutics (DXRX) Share Price, News & Analysis

Company Overview

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network®.

Key Stats

• Today's Range: 115 to 118
• 50-Day Range: 115 to 146.50
• 52-Week Range: 95 to 151
• Volume: 135,318 shs
• Average Volume: 111,909 shs
• Market Capitalization: £97.05 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: GBX 160
• Consensus Rating: Buy

Diaceutics Stock Analysis - MarketRank™

Diaceutics scored higher than 36% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Diaceutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Diaceutics has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Diaceutics is -34.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Diaceutics is -34.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Diaceutics has a P/B Ratio of 2.51. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for DXRX.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Diaceutics does not currently pay a dividend.

Dividend Growth

Diaceutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for DXRX.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Diaceutics this week, compared to 0 articles on an average week.

Company Ownership

• Score: 4.2 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Diaceutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought £16,217.10 in company stock and sold GBX 0 in company stock.

Percentage Held by Insiders

34.30% of the stock of Diaceutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

52.38% of the stock of Diaceutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

DXRX Stock Analysis - Frequently Asked Questions

How have DXRX shares performed this year?

Diaceutics' stock was trading at GBX 123 at the start of the year. Since then, DXRX shares have decreased by 6.5% and is now trading at GBX 115.
View the best growth stocks for 2025 here.

How do I buy shares of Diaceutics?

Shares of DXRX stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What other stocks do shareholders of Diaceutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Diaceutics investors own include 4D pharma (DDDD), Rolls-Royce Holdings plc (RR.L), Abcam (ABC), B&M European Value Retail (BME), BP (BP), Coats Group (COA) and genedrive (GDR).

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Diagnostics & Research
• Sub-Industry: N/A
• Current Symbol: LON:DXRX
• CIK: N/A
• Web: www.diaceutics.com
• Phone: N/A
• Fax: N/A
• Employees: 151
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: GBX 160
• High Stock Price Target: GBX 160
• Low Stock Price Target: GBX 160
• Potential Upside/Downside: +39.1%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Most Recent Fiscal Year): GBX (3.37)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 113.77
• P/E Growth: N/A
• Net Income: £-2,843,065.67
• Net Margins: -10.90%
• Pretax Margin: N/A
• Return on Equity: -7.15%
• Return on Assets: -6.06%

Debt

• Debt-to-Equity Ratio: 0.39
• Current Ratio: 4.85
• Quick Ratio: 9.92

Sales & Book Value

• Annual Sales: £26.08 million
• Price / Sales: 3.72
• Cash Flow: GBX 36.86 per share
• Price / Cash Flow: 3.12
• Book Value: GBX 45.87 per share
• Price / Book: 2.51

Miscellaneous

• Outstanding Shares: 84,393,829
• Free Float: N/A
• Market Cap: £97.05 million
• Optionable: Not Optionable
• Beta: 0.58